NO318387B1 - Anvendelse av en kombinasjon av en beta-reseptorblokker og et opioid ved behandling av smerte. - Google Patents
Anvendelse av en kombinasjon av en beta-reseptorblokker og et opioid ved behandling av smerte. Download PDFInfo
- Publication number
- NO318387B1 NO318387B1 NO19981222A NO981222A NO318387B1 NO 318387 B1 NO318387 B1 NO 318387B1 NO 19981222 A NO19981222 A NO 19981222A NO 981222 A NO981222 A NO 981222A NO 318387 B1 NO318387 B1 NO 318387B1
- Authority
- NO
- Norway
- Prior art keywords
- opioid
- receptor blocker
- combination
- pain
- alprenolol
- Prior art date
Links
- 230000036407 pain Effects 0.000 title claims abstract description 16
- 239000002876 beta blocker Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 28
- 239000003087 receptor blocking agent Substances 0.000 claims description 24
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 claims description 19
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical group C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims description 16
- 229960005181 morphine Drugs 0.000 claims description 14
- 229960002213 alprenolol Drugs 0.000 claims description 13
- 229960002428 fentanyl Drugs 0.000 claims description 10
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 10
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 10
- 229960002237 metoprolol Drugs 0.000 claims description 10
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 7
- 229960004739 sufentanil Drugs 0.000 claims description 6
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
- 229960000482 pethidine Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 3
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims description 3
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 claims description 3
- 229960001391 alfentanil Drugs 0.000 claims description 3
- 229960002274 atenolol Drugs 0.000 claims description 3
- 229960004324 betaxolol Drugs 0.000 claims description 3
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims description 3
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims description 3
- 229960002781 bisoprolol Drugs 0.000 claims description 3
- IPOPQVVNCFQFRK-UHFFFAOYSA-N phenoperidine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 claims description 3
- 229960004315 phenoperidine Drugs 0.000 claims description 3
- 229960002508 pindolol Drugs 0.000 claims description 3
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 3
- 229960003394 remifentanil Drugs 0.000 claims description 3
- 229960004605 timolol Drugs 0.000 claims description 3
- -1 sotal Chemical compound 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 9
- 239000003937 drug carrier Substances 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 description 12
- 230000001953 sensory effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229940005483 opioid analgesics Drugs 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000007913 intrathecal administration Methods 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 230000003502 anti-nociceptive effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 244000165918 Eucalyptus papuana Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001466453 Laminaria Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Compositions Of Oxide Ceramics (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9503476A SE9503476D0 (sv) | 1995-10-06 | 1995-10-06 | New combination |
| PCT/SE1996/001248 WO1997012634A1 (fr) | 1995-10-06 | 1996-10-03 | NOUVELLE COMBINAISON D'UN AGENT DE BLOCAGE DE β-RECEPTEUR ET D'UN OPIACE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO981222L NO981222L (no) | 1998-03-18 |
| NO981222D0 NO981222D0 (no) | 1998-03-18 |
| NO318387B1 true NO318387B1 (no) | 2005-03-14 |
Family
ID=20399727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19981222A NO318387B1 (no) | 1995-10-06 | 1998-03-18 | Anvendelse av en kombinasjon av en beta-reseptorblokker og et opioid ved behandling av smerte. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5908847A (fr) |
| EP (1) | EP0862462B1 (fr) |
| JP (1) | JP4135977B2 (fr) |
| AT (1) | ATE259657T1 (fr) |
| AU (1) | AU706794B2 (fr) |
| CA (1) | CA2233677C (fr) |
| DE (1) | DE69631597T2 (fr) |
| DK (1) | DK0862462T3 (fr) |
| ES (1) | ES2214548T3 (fr) |
| NO (1) | NO318387B1 (fr) |
| NZ (1) | NZ319746A (fr) |
| PT (1) | PT862462E (fr) |
| SE (1) | SE9503476D0 (fr) |
| WO (1) | WO1997012634A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100306707B1 (ko) * | 1998-09-07 | 2003-01-24 | 한국전기통신공사 | 교차이득변조형반도체광파장변환기 |
| US7041365B2 (en) * | 2003-05-12 | 2006-05-09 | 3M Innovative Properties Company | Static dissipative optical construction |
| JP2013523764A (ja) * | 2010-03-30 | 2013-06-17 | アルジーノミクス インコーポレイテッド | 体性感覚障害治療用の組成物と方法 |
| US8716350B2 (en) | 2010-03-30 | 2014-05-06 | Algynomics Inc. | Compositions and methods for the treatment of somatosensory disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885173A (en) * | 1985-05-01 | 1989-12-05 | University Of Utah | Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities |
-
1995
- 1995-10-06 SE SE9503476A patent/SE9503476D0/xx unknown
-
1996
- 1996-10-03 DE DE69631597T patent/DE69631597T2/de not_active Expired - Fee Related
- 1996-10-03 DK DK96933709T patent/DK0862462T3/da active
- 1996-10-03 NZ NZ319746A patent/NZ319746A/xx unknown
- 1996-10-03 AT AT96933709T patent/ATE259657T1/de not_active IP Right Cessation
- 1996-10-03 JP JP51420397A patent/JP4135977B2/ja not_active Expired - Fee Related
- 1996-10-03 EP EP96933709A patent/EP0862462B1/fr not_active Expired - Lifetime
- 1996-10-03 WO PCT/SE1996/001248 patent/WO1997012634A1/fr active IP Right Grant
- 1996-10-03 AU AU72335/96A patent/AU706794B2/en not_active Ceased
- 1996-10-03 US US08/765,133 patent/US5908847A/en not_active Expired - Lifetime
- 1996-10-03 CA CA002233677A patent/CA2233677C/fr not_active Expired - Fee Related
- 1996-10-03 ES ES96933709T patent/ES2214548T3/es not_active Expired - Lifetime
- 1996-10-03 PT PT96933709T patent/PT862462E/pt unknown
-
1998
- 1998-03-18 NO NO19981222A patent/NO318387B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU706794B2 (en) | 1999-06-24 |
| NO981222L (no) | 1998-03-18 |
| AU7233596A (en) | 1997-04-28 |
| WO1997012634A1 (fr) | 1997-04-10 |
| NO981222D0 (no) | 1998-03-18 |
| EP0862462A1 (fr) | 1998-09-09 |
| DE69631597T2 (de) | 2004-12-16 |
| US5908847A (en) | 1999-06-01 |
| DK0862462T3 (da) | 2004-05-10 |
| SE9503476D0 (sv) | 1995-10-06 |
| CA2233677C (fr) | 2006-08-29 |
| ES2214548T3 (es) | 2004-09-16 |
| NZ319746A (en) | 1999-11-29 |
| JP4135977B2 (ja) | 2008-08-20 |
| CA2233677A1 (fr) | 1997-04-10 |
| DE69631597D1 (de) | 2004-03-25 |
| JPH11513386A (ja) | 1999-11-16 |
| EP0862462B1 (fr) | 2004-02-18 |
| ATE259657T1 (de) | 2004-03-15 |
| PT862462E (pt) | 2004-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lewis et al. | Tramadol: a new centrally acting analgesic | |
| AU4992800A (en) | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects | |
| EA006384B1 (ru) | Композиция фентанила для интраназального введения | |
| CN1538846A (zh) | 用作止痛剂的6-羟基羟吗啡酮的口服给药 | |
| Collins et al. | The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans | |
| Mash | IUPHAR–invited review-Ibogaine–A legacy within the current renaissance of psychedelic therapy | |
| Brain et al. | A review of the history, actions, and legitimate uses of cocaine | |
| Westerling et al. | Morphine pharmacokinetics and effects on salivation and continuous reaction times in healthy volunteers | |
| NO318387B1 (no) | Anvendelse av en kombinasjon av en beta-reseptorblokker og et opioid ved behandling av smerte. | |
| Saeb-Parsy et al. | Instant pharmacology | |
| MX2007016065A (es) | Composicion farmaceutica novedosa y su uso en un metodo para el tratamiento de pacientes con congestion mucosal respiratoria superior. | |
| AU689577B2 (en) | New combination of a beta -receptor blocker and a local anaesthetic | |
| Patel et al. | Opioids for pain after oral surgery | |
| Dasgupta | Fighting the Opioid Epidemic: The Role of Providers and the Clinical Laboratory in Understanding Who is Vulnerable | |
| WO2005000203A2 (fr) | Methodes permettant de traiter la deficience cognitive et d'ameliorer la cognition | |
| Rappolt et al. | Use of Inderal (propranolol-Ayerst) in Ia (early stimulative) and Ib (advanced stimulative) classification of cocaine and other sympathomimetic reactions | |
| WANG et al. | The study of analgesics following single and repeated doses | |
| Mash | Ibogaine: Ibogaine therapy as a method of care treatment for opioid dependence | |
| WO1998038997A1 (fr) | Utilisation de la levobupivacaine en association avec des opioides ou des alfa2-agonistes comme anesthesiants ou analgesiques | |
| CN105878239A (zh) | 预防和治疗阿片类镇痛药止痛耐受性的紫堇达明药物组合物 | |
| CN109310691A (zh) | 用于快速开始抗抑郁作用的给药方案 | |
| Thomas et al. | Safety of enteral naloxone and iv neostigmine when used to relieve constipation. | |
| Matthew et al. | Analgesics: Opioids, Adjuvants and Others | |
| Kamath et al. | Comparison of Efficacy of Intrathecal Morphine 100µg and 200µg for Postoperative Pain Relief in Patients Undergoing Lower Abdominal and Lower Limb Surgeries | |
| US20020137767A1 (en) | Methods for treating addictive disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |